Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 30 Dec 2024 – 20 Aug 2026, limited by Bajaj Finserv Healthcare Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Bajaj Finserv Healthcare Fund | Nifty 500 |
|---|---|---|
| 30 Dec 2024 | ₹100.00 | ₹100.00 |
| 18 Feb 2025 | ₹88.52 | ₹92.19 |
| 09 Apr 2025 | ₹87.05 | ₹91.05 |
| 29 May 2025 | ₹94.07 | ₹102.26 |
| 17 Jul 2025 | ₹99.90 | ₹104.75 |
| 05 Sep 2025 | ₹98.31 | ₹102.11 |
| 25 Oct 2025 | ₹98.99 | ₹105.95 |
| 14 Dec 2025 | ₹98.04 | ₹106.12 |
| 02 Feb 2026 | ₹92.04 | ₹102.15 |
| 24 Mar 2026 | ₹92.35 | ₹94.23 |
| 12 May 2026 | ₹103.50 | ₹99.74 |
| 01 Jul 2026 | ₹110.14 | ₹103.37 |
| 20 Aug 2026 | ₹120.06 | ₹105.17 |
| Metric | Bajaj Finserv · Direct NAV ₹12.10 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +21.72% | +7.23% | |
| — | +16.94% | |
| — | +14.70% | |
| — | +15.10% | |
| +11.81% | +14.07% | |
| +27.78% | — | |
| — | +17.59% | |
| — | +16.29% | |
| — | +16.00% | |
| Risk | ||
| 13.52% | 15.69% | |
| 1.13 | 0.52 | |
| 1.53 | 0.73 | |
| -15.68% | -23.08% | |
| Nifty 500 | — | |
| — | +4.66% | |
| — | 0.96 | |
| — | 109.1% | |
| — | 91.0% | |
| 0.90% | 1.14% | |
| ₹329.96Cr | ₹1,161Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 41% | 45% | |
| Siddharth Chaudhary | — | |
| 30 Dec 2024 | — | |
| 33 | — | |
| 58.4% | — | |
| 1.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.